Vivos director gets 12,000 options at $0.18

Vivos Therapeutics, Inc. (VVOS) reported that director Leonard J. Sokolow received a grant of 12,000 stock options on September 14, 2026 at an exercise price of $0.18 per share, expiring September 14, 2036.

Available on EDGAR 09/18/2026 - 08:21 PM EDT Accepted by SEC EDGAR 09/18/2026 - 08:20 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Vivos Therapeutics, Inc. (VVOS) reported that director Leonard J. Sokolow received a grant of 12,000 stock options on September 14, 2026 at an exercise price of $0.18 per share, expiring September 14, 2036. One-half vested immediately, with one-fourth vesting on September 30, 2026 and one-fourth on December 31, 2026, bringing his directly held options to 17,600.

Insider Trade Summary

Grant/Award: 12,000 shares

Grant/Award 1 txn

Insider SOKOLOW LEONARD J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy) F1	12,000	$0.00	$0.00

Holdings After Transaction: Stock Options (Right to Buy) — 17,600 contracts (Direct)

Footnotes (1)

1. F1. On September 14, 2026 (the "Grant Date"), the Reporting Person received a grant of 12,000 stock options from the Issuer. One-half vested immediately (and the earliest possible exercise date in Table II relates to this tranche), one-fourth will vest on September 30, 2026 and one-fourth will vest on December 31, 2026. The options are exercisable for a period of 10 years from the Grant Date. Reflects expiry of 667 options on June 19, 2025 and 1,200 options on August 5, 2026, all of which expired unexercised.

Key Figures

Options granted: 12,000 options Exercise price: $0.18 per share Options held after transaction: 17,600 options +4 more

7 metrics

Options granted 12,000 options Grant to director on September 14, 2026

Exercise price $0.18 per share Stock options for VVOS common stock

Options held after transaction 17,600 options Director’s directly held options following the grant

Option expiration date September 14, 2036 End of 10-year exercisability period from grant date

Immediately vested options 6,000 options One-half of the 12,000 options vested on grant date

Options vesting on September 30, 2026 3,000 options One-fourth of the 12,000 options

Options vesting on December 31, 2026 3,000 options Final one-fourth of the 12,000 options

Key Terms

Stock Options (Right to Buy), Grant Date, vested, expiration date

4 terms

Stock Options (Right to Buy) financial

"security titled "Stock Options (Right to Buy)" reported for the grant"

Grant Date financial

"On September 14, 2026 (the "Grant Date"), the Reporting Person received"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

vested financial

"One-half vested immediately, one-fourth will vest on September 30, 2026"

expiration date financial

"The options are exercisable for a period of 10 years from the Grant Date"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did VVOS disclose for Leonard J. Sokolow?

VVOS disclosed that director Leonard J. Sokolow received a grant of 12,000 stock options on September 14, 2026 as a compensation-related award, with an exercise price of $0.18 per share and a 10-year term.

What is the vesting schedule of the new VVOS stock options granted to the director?

Of the 12,000 VVOS options granted, 6,000 vested immediately, 3,000 will vest on September 30, 2026, and 3,000 will vest on December 31, 2026. The options are exercisable for 10 years from the September 14, 2026 grant date.

What is the exercise price and expiration date of the VVOS options granted?

The granted VVOS stock options have an exercise price of $0.18 per share and are exercisable until September 14, 2036, which is 10 years from the grant date.

How many VVOS options does Leonard J. Sokolow hold after this grant?

After the September 14, 2026 grant, Leonard J. Sokolow directly holds 17,600 stock options for VVOS common stock, as reported in the filing.

Was the VVOS option grant to the director made under a Rule 10b5-1 trading plan?

The filing indicates the Rule 10b5-1 checkbox is not affirmed, and there is no footnote stating the grant was made pursuant to a Rule 10b5-1 trading plan.

Does the VVOS Form 4 mention any expired options for the director?

Yes. A footnote states that 667 options expired on June 19, 2025 and 1,200 options expired on August 5, 2026, all unexercised. These expirations are reflected in the reported post-grant option total.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SOKOLOW LEONARD J

(Last) (First) (Middle)

7921 SOUTHPARK PLAZA,

SUITE 210

(Street)

LITTLETON COLORADO 80120

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vivos Therapeutics, Inc. [ VVOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)(1)	$0.18	09/14/2026		A		12,000		09/14/2026(1)	09/14/2036	Common Stock	12,000	$0	17,600(1)	D

Explanation of Responses:

1. On September 14, 2026 (the "Grant Date"), the Reporting Person received a grant of 12,000 stock options from the Issuer. One-half vested immediately (and the earliest possible exercise date in Table II relates to this tranche), one-fourth will vest on September 30, 2026 and one-fourth will vest on December 31, 2026. The options are exercisable for a period of 10 years from the Grant Date. Reflects expiry of 667 options on June 19, 2025 and 1,200 options on August 5, 2026, all of which expired unexercised.

	/s/ Bradford K. Amman as attorney-in-fact for Leonard J. Sokolow	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)